Product Pipeline

Click on product names for information about Clinical Trials status.

Product Overview

We are an internationally integrated development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. Our vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (“haptenized”) to make them more visible to the patient’s immune system. We refer to our cancer vaccine technology as autologous cell vaccine immunotherapy and to the vaccine as the AC Vaccine.

The AC Vaccine is processed directly from the patients tumor. The tumor is broken down to the basic cancer cells. These cancer cells undergo a series of treatment steps and then the cells are modified with DNP, which attaches to the proteins on the surface of the cells. These DNP modified tumor cells are then re-administered to the patients with adjuvants in accordance with the previously optimized schedule of vaccine administration.

© 2008 AVAX Technologies, Inc. | Terms